Drug intelligence / Profile preview

Rivoltan

Development stage
Unknown
Lead developer
Krewel Meuselbach
Modality
Small Molecules
Administration
Oral
01

Overview

Rivoltan is a herbal pharmaceutical product developed and manufactured by Krewel Meuselbach. Its active ingredient is a dry extract derived from the root of Devil's Claw (*Harpagophytum procumbens*), with each film-coated tablet containing 480 mg of the extract. It is indicated for the supportive treatment of degenerative musculoskeletal disorders, including osteoarthritis, rheumatoid arthritis, and chronic back pain. The therapeutic effects are attributed to iridoid glycosides, such as harpagoside, which possess anti-inflammatory and analgesic properties. These compounds help reduce joint pain and improve mobility by inhibiting inflammatory mediators. Rivoltan is available as an over-the-counter (OTC) medication in Germany.

Brand names
RivoltanRivoltan Teufelskralle 480 mg
Other names
Harpagophytum procumbens root extractTeufelskrallenwurzel-TrockenextraktDevil's Claw root extract
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ALOX5 (Arachidonate 5-lipoxygenase)

Beyond the preview

Go deeper on Rivoltan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rivoltan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call